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Conclusions: New experimental data have been obtained at 
the ARRONAX cyclotron that permits to expand the 
knowledge of the tin-117m TTY up to 65 MeV. The results of 
the TALYS 1.6 code, which reproduce correctly the tin-117m 
production cross section, have been used to determine the 
tin-117m SA taking into account the stables and long live tin 
isotopes produced during the irradiation. The highest tin-
117m SA could be obtained using 40 MeV alpha beams which 
gives a TTY of 3.9 MBq/(µA.h). It is possible to get higher 
production yields but with a lower SA of the final product. 
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Purpose: Terbium is an element of growing interest for 
medical applications, considered as the “Swiss-knife of 
nuclear medicine” [1]. Indeed, four terbium radioisotopes 
can be used in nuclear medicine. Tb-149 is considered for 
alpha targeted therapy, Tb-161 for beta- targeted therapy, 
Tb-152 for Positron Emission Tomography (PET) and Tb-155 
for Single Photon Emission Computed Tomography (SPECT). 
However, terbium-155 can also be used as a radionuclide that 
emits Auger electrons for therapy. The interest on this 
radioisotope is increased by the conversion electrons emitted 
and the possibility to follow the treatment by SPECT imaging 
in a theranostic approach. The Tb-155 production has been 
investigated using the deuteron beam delivered by the 
ARRONAX cyclotron [2] and natural gadolinium target, 
motivated by the lack of data for this reaction at the 
beginning of our experiments. 
Materials/methods: Tb-155 production study has been 
considered at the ARRONAX cyclotron (France) taking 
advantage of the deuteron beam ranging from 15 to 35 MeV. 
Production cross section measurements of Tb-155 as well as 
radioactive contaminants have been made using the stacked-
foils technique. The stacks were made of thin natural 
gadolinium as targets, aluminum foils as degraders and thin 
natural titanium as monitor foils. After irradiation, the 
activity of each radionuclides produced in the foils has been 
determined by γ spectrometry [3]. From the cross section 
values obtained during these experiments, the Tb-155 Thick 
Target production Yield (TTY) has been calculated and 
compared with the other Tb-155 production routes using data 
available in the literature. When no experimental data were 
available, the TALYS code [4] version 1.6 helped to estimate 
the TTY. 
Results: In 2014, cross section values have been published for 
the Gd-nat(d,x)Tb-155 reaction [5]. Our set of data is in good 
agreement therewith. Tb-155 production cross section values 
for the Gd-nat(p,x) and Gd-nat(α,x) are also available in the 
literature. The Tb-155 TTY have been compared for each 
routes. Close values are obtained for the proton and the 
deuteron route. The Gd-nat(α,x) reaction gives the lowest 
TTY, whatever the incident beam energy. However, the use 
of a natural gadolinium target leads to the production of 
several contaminants and especially of Tb-156g which has the 
same half-life as Tb-155. Results based on calculations for 
two reactions using Gd-154 and Gd-155 enriched targets 
with, respectively, deuterons and protons as projectiles, are 
also discussed [3,6]. The Tb-159(p,5n)Dy-155(ε)Tb-155 
reaction, with results published in 2014 [7], is also discussed 
as a promising production route using high energy protons. 
Conclusions: New experimental data have been obtained at 
the ARRONAX cyclotron for the Gd-nat(d,x) reaction with a 
special emphasis on the Tb-155 production. The results have 
been compared with different production routes, using 
natural and enriched gadolinium target. Based on the 
calculations published in 2012 [6], the Gd-155(p,n) reaction 
seems to be the most promising for the production of Tb-155 
with gadolinium as target element. However, the Tb-
159(p,5n)Dy155(ε)Tb155 seems an interesting alternative. 
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Purpose: In this study, we report the rapid arc commissioning 
and dosimetric verification measurements performed with 
the electronic portal imaging device (EPID) having portal 
dosimetry software. 
Material and Methods: The dosimetric tests were performed 
on RapidArc capable Varian Unique linac, which is equipped 
with millennium 120 Dynamic Multi Leaf Collimators (DMLCs) 
and having 6 MV X-ray beam. The Varian RapidArc QA files, 
Eclipse treatment planning system (TPS) and EPID portal 
dosimetry system were used in this study. The RapidArc QA 
files incorporate following tests. 1) DMLC dosimetry. 2) 
Picket Fence (PF) test vs. gantry angle. 3) PF test during 
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Rapid Arc. 4) PF test during RapidArc with intentional errors. 
5) Accurate control of dose rate and gantry speed during 
RapidArc delivery. 6) Accurate control of leaf speed during 
RapidArc delivery. These RapidArc QA plans were loaded on 
Machine and analysed using EPID portal dosimetry system. 
Results and Discussion: Taking DMLC dosimetry, we measured 
meter reading at gantry angles 0°, 180°, 90° and 270° for a 
4x10 cm DMLC field with a 0.5 cm slit, and the effect of 
gravity on leaf position and linac head  showed maximum 
percentage deviation of -0.96% (± 2%). PF test at stationary 
gantry angles 0°, 180°, 90° and 270°, we evaluated the 
maximum DMLC positional shift of 0.5mm (± 1 mm). PF test 
during RapidArc (arc 179º-187º) has inspected the effect of 
gantry rotation on the MLC position, the result showed a 
maximum positional shift of -0.2 mm (± 1 mm). PF test during 
RapidArc with intentional errors have demonstrated that the 
test (3) can detect sub-millimetre errors during RapidArc. 
Accurate control of dose rate and gantry speed during 
RapidArc delivery has been examined by using 7 combinations 
of dose-rate, gantry range and gantry speed to give equal 
dose to seven 1.8 cm strips in a RapidArc field. When 
normalised to open field at same position (to exclude the 
beam profile influence), the dose of seven strips showed 
good result, with maximum mean deviation of 1.90% (< 2%). 
Accurate control of leaf speed during RapidArc delivery has 
been analysed by using 4 combinations of leaf speed (1.6, 
2.4, 0.8 and 0.4 cm/s) and dose-rate to give equal dose to 
four strips in a RapidArc field. When normalised to 
corresponding open field, the dose of four strips showed good 
result, with a maximum mean deviation of 1.74% (< 2%). All 
the test results showed good agreement with manufacture 
and published literature stated tolerance values (written in 
bracket in front of each result).The RapidArc commissioning 
data has also obtained an approval from Atomic Energy 
Regulatory Board (AERB), Mumbai, India. 
Conclusion: The dosimetric verification of DMLC movement, 
variable dose rates and gantry speed provides confidence 
over precision and accuracy during RapidArc delivery. These 
test are aimed only for commissioning and dosimetric 
verification of RapidArc enabled linac, and not for patient 
specific QA. 
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Purpose: Boost fields (A small field with isocentre blocked 
and less beam weightage) are routinely used in three 
dimensional conformal radiotherapy (3D-CRT) treatment 
plans of oesophagus, head and neck etc for enhancing PTV 
coverage. Challenges for using boost fields are associated 
with accuracy of treatment planning system (TPS) to 
calculate dose distribution, normalisation and monitor units 
(MUs) as isocentre is blocked so dosimetric verification of 
boost field is essential. The purpose of this study was to 
measure two things; first contribution of ‘Boost fields’ doses 
to the target isocentre, second doses to the region of 
interest of boost field and finally compare the dosimetrically 
measured data with TPS calculated data. 
Materials and Methods: Eclipse TPS (Version 8.6, Varian) was 
used for all boost fields 3D-CRT treatment plans in this study. 
The solid water phantom with dimension (25cmx25mx5cm), 
(25cmx25mx2cm) and (25cmx25mx5cm) respectively was 
used. The 0.65cc ionisation chamber was used for dosimetry 
in this study with SAD (source axis distance) setup. In boost 
fields study, five treatment plans of oesophagus case each 
having two plans with 6MV and 15MV and each plan having 
two boost fields (one is LPO boost field and other is RPO 
boost field) were performed. The contribution of boost field 
doses to the target isocentre for both 6MV and 15MV plans 
were measured with the help of ionisation chamber and also 
calculated in treatment planning system. The doses to the 
region of interest of boost field at 5cm depth in phantom 
were measured with help of thermoluminescence detector 
(TLD-100) and also calculated in treatment planning system 
for both 6MV and 15MV plans. Finally the measured and 
calculated data was compared. 
Results: Mean percentage variation between TPS calculated 
and ionisation chamber measured boost field doses to the 
target isocentre was 1.53% (SD 4.12) for 6MV and 4.13% (SD 
6.81) for 15MV. Maximum Percentage variation for this was 
6% and 12% for 6MV and 15MV respectively. Mean percentage 
variation between TPS calculated and TLDs measured boost 
field doses of region of interest of boost field was -1.22% (SD 
2.03) for 6MV and -0.4% (SD 2.84) for 15MV. Maximum 
percentage variation for this was 4% and 5% for 6MV and 
15MV respectively. TLDs were in good agreement with TPS. 
Results shows that contribution of boost field doses to the 
target isocentre for both 6MV and 15MV were less than 1cGy.  
Conclusion: Dosimetric verification of MUs delivered by boost 
fields is essential to verify the accuracy of TPS algorithms. 
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Purpose: In radionuclide therapy today mostly β−-labelled 
radiopharmaceuticals are used which irradiate the body 
internally with time-dependent dose-rate and can cause DNA 
double strand breaks (DSBs).  
The formation of a DNA DSB in nuclear chromatin results in 
the rapid phosphorylation of the histone variant gamma-
H2AX. DSBs also recruit the damage sensor 53BP1 to the 
chromatin surrounding the DSBs, which leads to 53BP1 and 
gamma-H2AX co-localization. By immunofluorescence 
staining with gamma-H2AX and 53BP1 antibodies those 
biomarkers can be addressed by microscopically visible foci.  
The number of foci per cell represent a quantitative 
biomarker for DNA double strand breaks and hence for 
radiation exposure and radiation effects. Presently, there are 
only few studies, which are studying the on-set and decay of 
DSBs after radionuclide therapy.  
The aim of our study was, therefore, to generate an in-vitro 
calibration curve for quantifying the dose-response of the 
number of radiation induced foci (RIF) after internal 
irradiation of blood with β−-emitters, and to describe 
comprehensively the dose-dependent time course of the DSB 
on-set and repair in lymphocytes of radiation treatment-
naive patients after radiopeptide therapy with 177Lu and 
radioiodine therapy with 131I. 
Material and Methods: For the in-vitro calibration with 131I 
and 177Lu blood samples were drawn from volunteers. 
Different activity concentrations were added, the samples 
were incubated for 1h to achieve absorbed doses up to 
100mGy, and the number of RIF/cell was determined.  
The patient studies addressed the relationship between the 
absorbed dose to the blood and the number and temporal 
behavior of radiation-induced DNA double strand breaks 
(RIF/cell) in multiple peripheral blood samples under 
radiopeptide therapy (16 patients) and under radioiodine 
therapy (20 patients).  
Results: The in-vitro study shows that the number of RIF/cell 
is linearly dependent of the absorbed dose, similar to what 
has been observed after external irradiation. 
In patients, the average number of RIF/cell showed a linear 
dose-response relationship within the first hours after 
administration of the radiopharmaceutical. Later time points 
were characterized by a diminishing number of radiation-
